文献速递神经肿瘤

IL-13Rα2/TGF-β双特异性CAR-T细胞对抗TGF-β介导的免疫抑制并增强胶质母细胞瘤的抗肿瘤反应

IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.
PubMed 文献 · Neuro Oncol · 2024-01-01

研究工程化靶向IL-13Rα2和TGF-β的双特异性CAR-T细胞,将TGF-β从免疫抑制剂转化为免疫刺激剂。在患者来源的胶质母细胞瘤异种移植和小鼠胶质瘤同源模型中,双特异性CAR-T细胞较传统IL-13Rα2 CAR-T细胞增加T细胞浸润、减少抑制性髓系细胞并改善生存。

要点

  • 双特异性IL-13Rα2/TGF-β CAR-T细胞可重编程肿瘤特异性T细胞对TGF-β的反应。
  • 较传统IL-13Rα2 CAR-T细胞,双特异性CAR-T细胞增加肿瘤脑内T细胞浸润并减少抑制性髓系细胞。
  • 在患者来源胶质母细胞瘤异种移植和小鼠胶质瘤同源模型中均改善生存。

核心结论

  • 重编程肿瘤特异性T细胞对TGF-β的反应,使双特异性IL-13Rα2/TGF-β CAR-T细胞抵抗并重塑免疫抑制性肿瘤微环境,从而在胶质母细胞瘤中驱动强效抗肿瘤反应。

研究设计与样本

  • 工程化靶向IL-13Rα2和TGF-β的单链双特异性CAR,在患者来源的胶质母细胞瘤异种移植和小鼠胶质瘤同源模型中评估疗效与安全性。

主要发现

  • 与常规IL-13Rα2 CAR-T细胞治疗相比,IL-13Rα2/TGF-β CAR-T细胞治疗导致荷瘤脑内T细胞浸润增加、抑制性髓系细胞 presence 减少,并在患者来源胶质母细胞瘤异种移植和小鼠胶质瘤同源模型中均改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapies targeting glioblastoma (GBM)-associated antigens such as interleukin-13 receptor subunit alpha-2 (IL-13Rα2) have achieved limited clinical efficacy to date, in part due to an immunosuppressive tumor microenvironment (TME) characterized by inhibitory molecules such as transforming growth factor-beta (TGF-β). The aim of this study was to engineer more potent GBM-targeting CAR-T cells by countering TGF-β-mediated immune suppression in the TME. METHODS: We engineered a single-chain, bispecific CAR targeting IL-13Rα2 and TGF-β, which programs tumor-specific T cells to convert TGF-β from an immunosuppressant to an immunostimulant. Bispecific IL-13Rα2/TGF-β CAR-T cells were evaluated for efficacy and safety against both patient-derived GBM xenografts and syngeneic models of murine glioma. RESULTS: Treatment with IL-13Rα2/TGF-β CAR-T cells leads to greater T-cell infiltration and reduced suppressive myeloid cell presence in the tumor-bearing brain compared to treatment with conventional IL-13Rα2 CAR-T cells, resulting in improved survival in both patient-derived GBM xenografts and syngeneic models of murine glioma. CONCLUSIONS: Our findings demonstrate that by reprogramming tumor-specific T-cell responses to TGF-β, bispecific IL-13Rα2/TGF-β CAR-T cells resist and remodel the immunosuppressive TME to drive potent anti-tumor responses in GBM.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Hou AJ, Shih RM, Uy BR, et al. IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro Oncol. 2024. PMID: 38982561. doi:10.1093/neuonc/noae126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。